Cargando…

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism

Congenital hyperinsulinism (HI), a beta cell disorder most commonly caused by inactivating mutations of beta cell K(ATP) channels, results in dysregulated insulin secretion and persistent hypoglycemia. Children with K(ATP)-HI are unresponsive to diazoxide, the only FDA-approved drug for HI, and util...

Descripción completa

Detalles Bibliográficos
Autores principales:	Juliana, Christine A., Chai, Jinghua, Arroyo, Pablo, Rico-Bautista, Elizabeth, Betz, Stephen F., De León, Diva D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318504/ https://www.ncbi.nlm.nih.gov/pubmed/37178920 http://dx.doi.org/10.1016/j.jbc.2023.104816

Ejemplares similares

Selective Somatostatin 5 (SST5) and Somatostatin 2 (SST2) Nonpeptide Agonists Potently Suppress Glucose- and Tolbutamide-Stimulated Dynamic Insulin Secretion From Isolated Human Islets
por: Rico, Elizabeth, et al.
Publicado: (2021)

SAT-260 Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Induced Insulin Secretion in Pancreatic Islets from both Rats and Healthy Human Donors
por: Rico-Bautista, Elizabeth, et al.
Publicado: (2019)

PSUN304 CRN04777 an Oral, Nonpeptide SST5-selective Somatostatin Agonist Dose Dependently Suppresses Basal and Stimulated Insulin Secretion
por: Ferrara-Cook, Christine, et al.
Publicado: (2022)

SAT-169 Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Glucose- and Sulfonylurea-Induced Insulin Secretion in Rats
por: Sturchler, Emmanuel, et al.
Publicado: (2019)

Somatostatin receptors in congenital hyperinsulinism: Biology to bedside
por: van Albada, Mirjam E., et al.
Publicado: (2022)

MON-089 Discovery and Identification of Late Stage Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists for the Treatment of Hyperinsulinemic Hypoglycemia
por: Fowler, Melissa A, et al.
Publicado: (2020)

Activation of Protein Kinase A (PKA) signaling mitigates congenital hyperinsulinism associated hypoglycemia in the Sur1(-/-) mouse model
por: Soundarapandian, Mangala M., et al.
Publicado: (2020)

SAT-364 Nonpeptide Orally-Bioavailable ACTH Antagonists: Suppression of ACTH-Induced Corticosterone Secretion and Adrenal Hypertrophy in Rats
por: Kusnetzow, Ana, et al.
Publicado: (2019)

The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism
por: Danowitz, Melinda, et al.
Publicado: (2022)

Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient
por: Banerjee, Indraneel, et al.
Publicado: (2017)

Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism
por: Peterson, Sean M., et al.
Publicado: (2023)

Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
por: Erickson-Miller, Connie L, et al.
Publicado: (2009)

A Nonpeptide Oxytocin Receptor Agonist for a Durable Relief of Inflammatory Pain
por: Hilfiger, Louis, et al.
Publicado: (2020)

OR12-2 Inhibition of Basal and ACTH-stimulated Cortisol Secretion in Humans Using an Oral Nonpeptide ACTH Antagonist (CRN04894)
por: Betz, Stephen, et al.
Publicado: (2022)

Mutations in UCP2 in Congenital Hyperinsulinism Reveal a Role for Regulation of Insulin Secretion
por: González-Barroso, M. Mar, et al.
Publicado: (2008)

Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers
por: Madan, Ajay, et al.
Publicado: (2022)

Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge
por: Stefanovski, Darko, et al.
Publicado: (2022)

SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers
por: Madan, Ajay, et al.
Publicado: (2019)

Phenotypic Characterization of Congenital Hyperinsulinism Due to Novel Activating Glucokinase Mutations
por: Li, Changhong, et al.
Publicado: (2023)

In vitro pharmacological characterization of a novel unbiased NOP receptor‐selective nonpeptide agonist AT‐403
por: Ferrari, Federica, et al.
Publicado: (2017)

Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
por: Kawai, Takahiro, et al.
Publicado: (2020)

MON-176 Discovery and Identification of Late Stage Selective Nonpeptide ACTH Antagonists for the Treatment of Cushing’s Disease, Ectopic ACTH Secreting Tumors, and Congenital Adrenal Hyperplasia
por: Kusnetzow, Ana Karin, et al.
Publicado: (2020)

Characterizing the neurological phenotype of the hyperinsulinism hyperammonemia syndrome
por: Rosenfeld, Elizabeth, et al.
Publicado: (2022)

Mosaic GLUD1 Mutations Associated with Hyperinsulinism Hyperammonemia Syndrome
por: Boodhansingh, Kara E., et al.
Publicado: (2022)

Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury
por: Barroso, Lívia Corrêa, et al.
Publicado: (2012)

Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors
por: Journigan, V. Blair, et al.
Publicado: (2014)

Somatostatin-secreting Pheochromocytoma Mimicking Insulin-dependent Diabetes Mellitus
por: Hirai, Hiroyuki, et al.
Publicado: (2016)

Natural history and neurodevelopmental outcomes in perinatal stress induced hyperinsulinism
por: Sigal, Winnie M., et al.
Publicado: (2022)

OR05-2 Targeted Inhibition of Glutamate Dehydrogenase by Alpha-Tocopherol: A Potential Novel Treatment for Hyperinsulinism Hyperammonemia Syndrome
por: Rosenfeld, Elizabeth, et al.
Publicado: (2019)

Correction: Characterizing the neurological phenotype of the hyperinsulinism hyperammonemia syndrome
por: Rosenfeld, Elizabeth, et al.
Publicado: (2022)

SAT182 Effects Of An Orally Bioavailable Nonpeptide Parathyroid Hormone Receptor Type 1 (PTH1R) Antagonist In Rodent Models Of Primary Hyperparathyroidism (PHPT)
por: Antwan, Agnes S, et al.
Publicado: (2023)

Basal hypersecretion of glucagon and insulin from palmitate-exposed human islets depends on FFAR1 but not decreased somatostatin secretion
por: Kristinsson, H., et al.
Publicado: (2017)

OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of (14)C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly
por: Madan, Ajay, et al.
Publicado: (2020)

MON-087 Natural History and Neurodevelopmental Outcomes in Perinatal Stress Induced Hyperinsulinism
por: Sigal, Winnie M, et al.
Publicado: (2020)

Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families
por: Banerjee, Indraneel, et al.
Publicado: (2022)

Hyperinsulinism
Publicado: (1932)

Correction to: Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families
por: Banerjee, Indraneel, et al.
Publicado: (2022)

Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion
por: van der Meulen, Talitha, et al.
Publicado: (2015)

Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
por: Vergari, Elisa, et al.
Publicado: (2019)

Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures
por: Merlino, Francesco, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8ohp2k23et17i3la9h97c0h92n